Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
January 20, 2021 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
January 14, 2021 07:30 ET | Kaleido Biosciences
Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P....
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19
January 04, 2021 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that completion of enrollment of 350 subjects in the controlled clinical study K031...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 15:00 ET | Kaleido Biosciences
LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 02, 2020 07:35 ET | Kaleido Biosciences
- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 2021 - LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc....
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Data from MMT Programs Accepted for Presentation at Upcoming Scientific Conferences
October 07, 2020 07:30 ET | Kaleido Biosciences
Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020 Data from studies of KB39 and KB174 to be presented at The Liver Meeting®...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline
October 06, 2020 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer
October 01, 2020 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis
September 29, 2020 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that the first patient has been dosed in its clinical study evaluating Microbiome...